CDH1 gene as a prognostic biomarker in HCV (genotype 4) induced hepatocellular carcinoma in the Egyptian patients

Gene Reports ◽  
2019 ◽  
Vol 16 ◽  
pp. 100452
Author(s):  
Rady E. El-Araby ◽  
Mahmoud A. Khalifa ◽  
Mona M. Zoheiry ◽  
Manal Y. Zahran ◽  
Mohamed I. Rady ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Biomarker ◽  
Cdh1 Gene ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients

scholarly journals MMP9 and CEBPα Genes as a New Prognostic Biomarker for Hepatocellular Carcinoma Caused by Infection with HCV-Genotype (4)

2021 ◽  
pp. 1-7
Author(s):  
Rady Eid El-Araby ◽  
Rabab S. Hamad ◽  
Najla K. Al Abdulsalam ◽  
Ahmed R. Mashaal ◽  
Rady Eid El-Araby
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Bioinformatics Analysis ◽  
Prognostic Biomarker ◽  
Main Type ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients ◽  
Healthy Control ◽  
Diagnostic Capacity

Hepatocellular carcinoma (HCC) remains the main type of liver cancer. Understanding the molecular and immune mechanisms of HCC tumorigenesis are required to develop effective biomarkers. This study is designed to measure the circulating MMP9 and CEBPα to provide a diagnostic and prognostic biomarker for HCV-genotype (4) induced liver cirrhosis and carcinogenesis. This study included one hundred Egyptian patients, divided into two groups 50 patients each. The first group: classified into Chronic Liver Disease (CLD) without cirrhosis (n=25) and CLD with cirrhosis (n=25). The second group: classified into CLD patients with HCC, (n=25), and healthy control (25 volunteers). The expression of MMP9 and CEBPα genes were analysed using Real-Time PCR. Our results showed significant downregulation in MMP9 and CEBPα genes in cirrhotic and HCC patients (p< 0.001 and p<0.001) respectively. There was a significant (p< 0.001) diagnostic capacity between HCC patients against CLD with or without cirrhosis patients. Bioinformatics analysis revealed a relationship between MMP9 and CEBPα genes. In conclusion, the gradual decrease in the expression of MMP9 and CEBPα gene during the progression of the disease recommended use of MMP9 and CEBPα genes as a diagnostic and prognostic biomarker for both cirrhosis and HCC in HCV-genotype (4) patients.

scholarly journals MicroRNA-122a as a non-invasive biomarker for HCV genotype 4-related hepatocellular carcinoma in Egyptian patients

2019 ◽  
Vol 15 (6) ◽  
pp. 1454-1461 ◽  
Author(s):  
Eman El-Ahwany ◽  
Lobna Mourad ◽  
Mona Zoheiry ◽  
Hoda Abu-Taleb ◽  
Marwa Hassan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Non Invasive ◽  
Egyptian Patients

Insulin resistance: a predictor for response to interferon-based therapy in Egyptian patients with chronic HCV genotype 4

2012 ◽  
Vol 23 (1) ◽  
pp. 7-13
Author(s):  
Sherif Mogawer ◽  
Mona Mansour ◽  
Mohamed Marie ◽  
Mervat El-Ansary ◽  
Samah Abd El-Hamid
Keyword(s):  
Insulin Resistance ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Egyptian Patients ◽  
Chronic Hcv

scholarly journals Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4

PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153895 ◽  
Author(s):  
Hanan H. Rizk ◽  
Nadia M. Hamdy ◽  
Nadia L. Al-Ansari ◽  
Hala O. El-Mesallamy
Keyword(s):  
Genotype 4 ◽  
Hcv Genotype ◽  
Predictors Of Response ◽  
Egyptian Patients

scholarly journals Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis

2006 ◽  
Vol 13 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Gamal Badra ◽  
Imam Waked ◽  
Carlo Selmi ◽  
Saleh M. Saleh ◽  
Ahmed El-Shaarawy ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Middle Eastern ◽  
Interferon Α ◽  
Serum Samples ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Ifna Therapy ◽  
Egyptian Patients

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.

Sign in / Sign up

Export Citation Format

Share Document